Blood Cancer Talks

In this episode, we dissect some of the key practice-changing abstracts from ASH 2022 in lymphoma and chronic lymphocytic leukemia with Dr. Toby Eyre.

Show Notes

ALPINE Trial: Zanubrutinib vs Ibrutinib in Relapsed/Refractory CLL (
CLL2-Give Trial: Updated results Obinutuzumab (G), Ibrutinib (I), and Venetoclax (Ve) triplet in Untreated Patients with CLL with 17p Deletion/TP53 Mutation ( 
AVO Trial: Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease ( 
Watch-and-Wait RCT in Follicular Lymphoma: Long-term follow-up of Phase 3 Study of Rituximab Versus a Watch and Wait Approach for Patients with Asymptomatic, Low Tumour Burden Follicular Lymphoma (
Augment Trial: Update of Phase 3 RCT comparing Rituximab-Revlimid (R2) vs Rituximab-Placebo in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (
TRIANGLE Study: Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma (

What is Blood Cancer Talks?

This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth.
Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston
Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk